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Dr. Nash,
I just finished reading your editorial in the most recent Office of Health Policy Newsletter. It is
one of the most clear-headed calls to action that I have read on such a complex topic.
I have worked in the Medicare arena for over 20 years, the past six years as the head of the
largest M+C health plan in Minnesota and now as the CEO of the Peer Review Organization in
Minnesota, Stratis Health. I have testified to Congress about the inequity of the current
Medicare reimbursement system that allows drugs to be covered in some markets, but not in
efficient ones like Minnesota. Thank you for weighing in on this subject and for encouraging
others to get involved as well. You should submit your editorial to The New York Times. It is
very well written and you have made it easy to understand the issue.
Patricia Riley, CEO
Stratis Health
Minneapolis, MN
Mnpro.priley@sdps.org
*
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Dr. Nash,
Your editorial in the Office of Health Policy Newsletter, “Drug Benefits in Medicare: Where Are
We Headed?” was excellent.
Oliver E. Owen, MD
*

*

*

Dr. Nash,
I read your June 2000 article, “Drug Benefits in Medicare : Wh e re are We Headed?” with
great interest . As long as pharmaceutical companies continue to pour $80 million into political
campaigns each year, I won’t be waiting for Congress to force them to:
•
•
•

Change the rules that cur rently allow the first pharmaceutical company to develop a
generic to be paid by the original patent holder and marketing a generic substitute;
Change their domestic and international pricing structure; and
Demonstrate through scientific evidence, improved performance of a new drug over
existing drugs.

John C. Greene
*

*
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Dr. Nash,
I loved your editorial on Medicare prescription benefits. Clearly the cost of drugs is spiraling
out of control and clearly the US consumer is subsidizing international consumers. It’s a
complex issue since the profitability of drug companies, their stock prices and many
retirement funds are inter-linked, but the need for information that links cost and outcomes
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has never been greater. As consumers and their physicians make decisions about drug plans
and drug choices, they need to understand if the regimen of choice is “worth it.”
Randy L. Thomas
Eclipsys Corporation
*

*
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Please note: The comments expressed by the authors in this publication do not
necessarily represent the views of the Editorial Board, Thomas Jefferson University,
Jefferson Medical College, Jefferson Health System or of the
Office of Health Policy and Clinical Outcomes.
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